HIGHLIGHTS
- who: HBsAg et al. from the University of Cambridge, United Kingdom have published the research: Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity, in the Journal: (JOURNAL)
- how: All the animal experiments were carried out in accordance with the guidelines of the Chinese Council on Animal Care and approved by the Chongqing Medical University. The results showed that the HBsAg level in cell supernatant was reduced by Pim treatment in a dose dependent manner. Consistently the data showed that Pim significantly reduced SpI SpII and core promoter activities. The results showed that . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.